Volume 8 Issue 142
Published - 14:00 UTC 08:00 EST 22-May-2006 
Next Update - 14:00 UTC 08:00 EST 23-May-2006

Editor: Susan K. Boyer, RN
Vidyya.
All rights reserved.

We subscribe to the HONcode principles. Verify here.

  

 


Researchers uncover new mechanism of tumor suppressor

Researchers from the University of Colorado-Denver and Health Sciences Center and Stanford University have discovered a molecular mechanism that explains how cells respond to DNA damage and other acute stresses, and if disrupted can cause cancer. Their findings, which could lead to new diagnostic markers and cancer treatments with fewer side effects, will appear in two reports in the May 21 advanced online version of the journal Nature. more  

Bariatric surgery at the extremes of age

Approximately 17 percent of children and adolescents and 32 percent of adults in the United States are considered obese, with obesity among adolescents and older adults rising dramatically. While gastric surgeries are soaring in popularity, the safety and efficacy of the surgery for certain patient populations has been questioned. more

Randomized controlled trial of laparoscopic Nissen fundolplication (LNF) versus proton pump inhibitors for treatment of patients with chronic gastro-esophageal reflux disease (GERD)

Gastroesophageal reflux disease (GERD), a chronic gastrointestinal disease that affects more than seven million people in the United States, is most commonly treated with medication or surgery to manage disease symptoms. more  

Injecting stem cells from a woman's own muscle may effectively treat urinary incontinence

In the first clinical study of its kind in North America, women with stress urinary incontinence (SUI) were treated using muscle-derived stem cell injections to strengthen deficient sphincter muscles responsible for the condition. Results of the study, led by researchers at the University of Pittsburgh School of Medicine and Sunnybrook Health Sciences Centre in Toronto, suggest that the approach is safe, improves patients' quality of life and may be an effective treatment for SUI. more

Valopicitabine (NM283), alone or with Peg-Interferon, compared to Peg Interferon/Ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to PegIFN/RBV 

More than half of currently treated hepatitis patients are infected with strains of hepatitis C that do not respond to current interferon therapies and have no other effective treatment options. Combination treatment using a new antiviral therapy is showing promise in suppressing the virus, according to a phase II US multi-center study. The therapy, valopicitabine, has shown anti-HCV activity alone and in combination with pegIFN (pegylated interferon) in early trials, without viral breakthrough for study periods up to six months. more

Comparison of daily Consensus Interferon versus Peginterferon alfa 2a extended therapy of 72 weeks for peginterferon / ribavirin relapse patients with chronic hepatitis C  

In chronic diseases like hepatitis, symptoms have a tendency to fluctuate in severity. As a result, researchers are finding that the diseases may react more successfully to a longer duration of therapy. In this study, researchers at the University of Tuebingen in Germany compared two combination therapies for an extended treatment period of 72 weeks, compared to the current standard of 48 weeks, in patients with chronic hepatitis C. more

Acetaminophen as a co-factor in acute liver failure due to viral hepatitis determined by measurement of acetaminophen-protein adducts

Acetaminophen (APAP) is a common over-the-counter medication present in more than 300 preparations for pain relief and flu-like symptoms. But for people who are suffering from viral hepatitis A or B, use of acetaminophen may play a role in accelerating liver failure, ordinarily a rare complication of viral hepatitis. more

 

For people who are suffering from viral hepatitis A or B, use of acetaminophen may play a role in accelerating liver failure, ordinarily a rare complication of viral hepatitis.